

## Übersicht Klinische Studien ab 08/2014 – Prof. Dr. Ezziddin

Nr.	Studienname	Sponsor	EudraCT-Nr.	Phase	Titel	Hauptprüfarzt
1	Columbus	Novartis	2013-001176-38	3	A phase III randomized , 3-arm, open label , multicenter study of LGX818 plus MEK 162 and LGX818 monotherapy compared with vemurafenib in patients with unresentable or metastatic BRAF V600 mutant melanoma	Prof. Dr. Vogt
2	PRA: SGN35-014	Seattle Genetics	2012-002751-42	3	A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients with CD30-positive T-cell lymphomas	Prof. Dr. Pfreundschuh
3	CA209-139	BMS Int. Corp.	2013-003645-42	2	A single-arm,Phase2 study of Nivolumab(BMS-936558) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplantat(ASCT) or After Failureof at least two Prior Multi-agent Chemotherapie Regimens in Subjects who are not Candidates for ASCT	Prof. Dr. Pfreundschuh
4	CA209-140	BMS Int. Corp.	2013-003621-28	2	A single-arm , Open-Label Phase 2 Study of Nivolumab(BMS-936558) in Subjects with relapsed or Refractory Follicular Lymphoma (FL)	Prof. Dr. Pfreundschuh
5	AFM11-101	Affimed Therapeutics AG	2013-001919-78		A Pharmacodynamically guided, dose-escalation, phase! Study to access the safety of AFM11(recombinant antibody construct against human CD19 and CD3) in patients with relapsed and/or refractory CD19 positive B-cell NHL and adult B-precursor ALL	Prof. Dr. Pfreundschuh
6	CA184-437	BMS Int. Corp.	2014-002987-34	2	A Phase2, randomized,Double-Blind Study of Ipilimumab Administered at b3mg/kg vs 10 mg/kg in Adult Subjects with Metastatic Chemotherapy-Naïve Castration Resistent prostate Cancer who are Asymptomatic or Minimally Symptomatic	Dr. Ohlmann
7	Optimal >60	Universität des Saarlandes	2010-019587-36		Improvement of Outcome and Reduction of Toxicity in Elderly Patients with CD20+ Aggressive B-Cell Lymphoma by an Optimised Schedule of the Monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET based Reduction of Therapy in Combination with	Prof. Dr. Heldt

					Vitamin D Substitution	
<b>8</b>	XOFIGO REassure	Bayer	ImPACT: 16913		REASSURE - Radium-223 alpha Emitter Agent in Safety Study in mCRPC popUlation for long-teRm Evaluation	Prof. Ezziddin
<b>9</b>	MM302-02-02-03	Merrimack	2014-003159-73		A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician's Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer	Prof. Solomeyr
<b>10</b>	Amaranth AZD3293	Eli Lilly Parexel	<b>2014-002601-38</b>		A 24-month, Multcenter, Randomized, Double-blind, Placebo-controlled, parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's disease	Prof. Dr. Riemenschneider
<b>11</b>	SOLAR-1 (CBY719C2301)	Novartis	2015-000340-42	3	A phase III randomised double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive ,HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment	Prof. Dr. Solomeyr
<b>12</b>	B7391003 (PF06439535)	Pfizer	2014-003878-16	3	A Phase3 Randomized, Double-Blind Study of PF-6439535 plus Paclitaxel-carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-Line Treatment of Patients with advanced non Scamous Non-Small Cell Lung Cancer	Prof. Dr. Wehler
<b>13</b>	14T-MC-JVDC	Lilly	2014-003655-66	3	A Phase 3 , Randomized, Double-blind, Placebo-Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy	Prof. Dr. Stöckle
<b>14</b>	MK3475	MSD	2015-0033644-40	1/2	A Phase I/II Trial of Pembrolizumab( MK-3475)in Combination with Chemotherapy, Immunotherapy, and targeted Therapies in Metastatic Castration-Resistant Prostate Cancer(mCRPC)	PD Dr. Heinzlbecker
<b>15</b>	C16021	Millenium	2014-001394-13	3	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients with newly Diagnosed Multiple Myeloma Not Treated with Stem Cell Transplantation	Prof. Dr. Pfreundschuh
<b>16</b>	CINC280B2201	Novartis	2015-001241-84	1b/2	A phase Ib/II, open-label, multicenter trial with oral cMET inhibitor INC280 alone and in combination with erlotinib versus platinum/pemetrexed in adult patients with EGFR mutated, cMET-amplified, locally advanced/metastatic nonsmall cell lung cancer	Prof. Dr. Wehler

					(NSCLC) with acquired resistance to prior EGFR tyrosine kinase inhibitor (EGFR TKI)	
<b>17</b>	GO29436	LaRoche	2014-003207-30	3	A Phase III, Open-Label Study of MPDL3280A(Anti-PD-L1 Antibody) in Combination with Carboplatin+ Pacitaxel with or without Bevacizumab compared with Carboplatin+ Paclitaxel+ Bevacizumab in Chemotherapy naïve Patients with Stage IV Non-Squamous Non Small Cell Lung Cancer	Prof. Dr. Wehler
<b>18</b>	GO29437	HLR	2014-003208-59	3	A Phase III, Open-Label , multicenter, randomized study evaluating the efficacy and safety of MPDL3280A(Anti-PD-L1 antibody) in combination with Carboplatin*Paclitaxel or MPDL3280A in combination with Carboplatin+NAB Paclitaxel vs. Carboplatin* NAB-Paclitaxel in chemotherapy naïve patients with stage IV squamous NSCLC	Prof. Dr. Wehler
<b>19</b>	CINC280A2201	Novartis	2014-003850-15	2	A phase II, multicenter, three-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease	Prof. Dr. Wehler
<b>21</b>	S8B-G31-NSCLC	Samsung	2015-004026-34	3	A Phase III, Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB8 (proposed bevacizumab biosimilar) and Avastin® in Subjects with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer	Prof. Dr. Wehler
<b>22</b>	Galahad-PCR 2001	Janssen- Cilag	2016-002057-38	2	A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA- Repair Anomalies	Prof. Dr. Stöckle
<b>23</b>	TS102-EPOCH	Biocompatibles	CIV-11-12-003422	3	A Phase III Clinical Trial Evaluating TheraSphere in Patients with Metastatic Colorectal Carcinoma of the Liver who have failed first Line Chemotherapy	Prof. Dr. Lammert
<b>24</b>	TS-103 Stop HCC	Biocompatibles	CIV-12-10-008943	3	A Phase III Clinical Trial of INTRA- arterial TheraSphere in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC)	Prof. Dr. Lammert
<b>25</b>	LPS14201 CARD	Sanofi	2014-004676-29		Prüfung LPS14201 - CARD „A randomized, open label, multicenter study of Cabazitaxel versus an Androgen Receptor (AR)-targeted agent (abiraterone or enzalutamide) in mCRPC patients previously treated with Docetaxel and who rapidly failed a prior AR-targeted agent	Prof. Dr. Stöckle

<b>26</b>	COMPETE Study	ITM/ABX CRO	2016-001897-13	3	A prospective, randomized, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy(PRRT) with <sup>177</sup> Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive(SSTR <sup>+</sup> ), neuroendocrine tumours of gastroenteric or pancreatic origin(GEP-NET)	Prof. Dr. Ezziddin
<b>27</b>	E2609-G000-301	Inventiv Health Clinical	2016-003928-23	3	A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer's Disease	Prof. Dr. Riemenschneider
<b>28</b>	BN29553	Roche	2016-003288-20	3	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease BN29553 Protokoll Nr. Amyloid PET BN59223- Amyloid PET Longitudinal Study	Prof. Dr. Riemenschneider
<b>29</b>	MEDI4736-NHL- 1	Celgene	2015-0035116-21	1/2	A phase 1/2 , open label, multicenter study to assess the safety and tolerability of Durvalumab(Anti-PD-L1 Antibody) as Monotherapy and in combination therapy in subjects with lymphoma or chronicx lymphocytic leukemia	Prof. Dr. Pfreundschuh
<b>30</b>	B7461006	Pfizer	2016-003315-35	3	A randomized, open-label Phase 3 study of Lorlatinib (PF-06463922) monotherapy versus CRIZOTINIB monotherapy in the first-line treatment of patients with advanced ALK-positive non-Small-cell lung cancer	Prof. Dr. Wehler
<b>31</b>	WN29922	Roche Pharma AG	2017-001364-38	3	A Phase III, multicenter, randomized, double-blind, Placebo-controlled, parallel-group, Efficacy and Safety Study of Gantenerumab in patients with Prodromal to Mild Alzheimer Disease	Prof. Dr. Riemenschneider
<b>32</b>	MOR208C204 B-mind	MorphoSys AG	2014-004689-11	2/3	A Phase II/III, randomized, multi-center Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with relapsed or refractory diffuse Large B-Cell Lymphoma(R-R DLBCL) who are not eligible for High Dose Chemotherapie (HDC) and autologous Stem-cell transplantation	Prof. Dr. Stilgenbauer
<b>33</b>	PCYC-11-43-CA	Pharmalytics LLC	2017-000129-12	3	Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma	PD Dr. Bittenbring
<b>34</b>	PACIFIC-4	AstraZeneca	2018-002572	3	A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab	PI Dr. Henschke

					Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer	
<b>35</b>	PROTEUS JNJ-56021927PCR3011	Janssen-Cilag	2018-001746-34	3	A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with Highrisk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy	PI Dr. Heinzelbecker
<b>36</b>	Magnitude Protocol 64091742PCR3001	Janssen-Cilag	2017-003364-12	3	A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer	PI Dr. Heinzelbecker
<b>37</b>	Lymrit 37-01/3185-0002	Nordic Nanovector ASA	2011-000033-36	2b	A phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) antibodyradionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma.	PI Dr. Jacobs Saarbrücken
<b>38</b>	Primo VS-0145-225	Verastem	2019-001123-13	2	A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)	PI Prof. Dr. Stilgenbauer
<b>39</b>	ION-682884-CS2	IONIS Pharmaceuticals	2019-002835-27	3	A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)	PI Prof. Dr. Kindermann
<b>40</b>	BGB-11417-101	BeiGene Ltd.	2019-002835-27	1/1b	A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies	PI Prof. Dr. Stilgenbauer
<b>41</b>	CA209-7FL	Bristol Myers Squibb	2017-000129-12	3	A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal	Prof. Dr. Solomeyer

					Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer	
--	--	--	--	--	---	--